qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Launched by UNIVERSITY OF WISCONSIN, MADISON · May 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new method called quantitative digital subtraction angiography (qDSA) to measure blood flow during a procedure known as liver transarterial embolization. This procedure is used to treat liver tumors by blocking the blood supply to them. The qDSA technique could help doctors make sure they are reducing the blood flow to the tumor the right amount, which is important for effective treatment. The study will include up to 20 participants who will visit the study site once and be monitored for up to six months.

To participate, individuals should be between the ages of 65 and 74, be able to give informed consent (meaning they understand and agree to the study), and not have certain health issues like pregnancy, severe kidney problems, or allergies to contrast dye used in imaging tests. Participants can expect to be part of a study that aims to improve treatment for liver tumors, and they will be carefully evaluated throughout the process to ensure their safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule
• Exclusion Criteria:
• • Pregnancy or breastfeeding
• • Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
• • Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
• • Patients with a physical or psychological condition that would impair study participation.
• • The patient is judged unsuitable for study participation by the Investigator for any other reason